- Subjects with high-risk cardiac/vascular disease unable to tolerate pazopanib, e.g. uncontrolled hypertension (>160 systolic blood pressure or >100 diastolic blood pressure); Class III/IV congestive heart failure per NYHA classification; or unstable angina or stroke.